PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	CHANGE OF NAME

CONVEYING PARTY DATA

Name	Execution Date
Sanofi-Synthelabo	08/20/2004

RECEIVING PARTY DATA

Name:	sanofi-aventis
Street Address:	174 Avenue de France
City:	Paris
State/Country:	FRANCE
Postal Code:	75013

PROPERTY NUMBERS Total: 3

Property Type	Number
Application Number:	11185230
Application Number:	11183599
Application Number:	13027425

CORRESPONDENCE DATA

Fax Number:	9089817832
Phone:	908-981-6998
Email:	USPatent.E-Filing@sanofi.com

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.

Correspondent Name:	Robin J. Inman
Address Line 1:	55 Corporate Drive
Address Line 2:	Mail Code: 55A-505A
Address Line 4:	Bridgewater, NEW JERSEY 08807

ATTORNEY DOCKET NUMBER:	IVD924 US CNT; DIV; DIV3
NAME OF SUBMITTER:	Robin J. Inman

Total Attachments: 3
source=Name Change - Sanofi-Synthelabo to Sanofi-Aventis 08-20-2004#page1.tif
source=Name Change - Sanofi-Synthelabo to Sanofi-Aventis 08-20-2004#page2.tif
source=Name Change - Sanofi-Synthelabo to Sanofi-Aventis 08-20-2004#page3.tif

CH $120.00 11185230

DECISION
DATED 20 AUGUST 2004

The undersigned, Jean-François Dehecq,

Acting in his capacity as Chairman and Managing Director of Sanofi-Synthélabo, a *société anonyme* with a capital of EUR 2 748 900 914, with registered office at 174, avenue de France, 75013 Paris, registered under number 395 030 844 RCS Paris (the "**Company**"),

And by virtue of the conferral of powers upon him by the Board of Directors of the Company at its meeting held on 23 June 2004, under the conditions set forth below,

Hereby states that:

1. By a vote on the fifteenth resolution, which was subject to it, the General Assembly of Shareholders of the Company, meeting on 23 June 2004:

   - decided to change the trade name of the Company and to adopt that of "Sanofi-Aventis", subject to the suspensive condition of completion of the settlement/delivery of offers initiated by the company in France (the "**Offer**"), Germany and the United States of America for the account of Aventis (together, the "**Offers**"), and with effect on that date, and

   - consequently decided, with the same reserves and with effect on the same date, to replace the current wording of Article 2 of the Articles of Association, with the following

     "Article 2 - Name:

     The Company shall have the trade name "Sanofi-Aventis".

2. By a vote on the twenty-seventh to thirty-fourth resolutions, the General Meeting of Shareholders of the Company, meeting on 23 June 2004,

appointed Jean-Marc Bruel, Jürgen Dormann, Jean-René Fourtou, Serge Kampf, Igor Landau, Hubert Markl, Klaus Pohle and Hermann Scholl as directors, subject to the suspensive condition of completion of the settlement/delivery of the Offers, and with effect on that date, for a period of four years to expire after the meeting called to rule on the accounts for the 2007 financial year.

3. The Board of Directors of Sanofi-Synthélabo, at its meeting of 23 June 2004, conferred upon its Chairman and Managing Director, Jean-François Dehecq, the power to record lifting of the suspensive condition to which the decisions of the above-mentioned General Meeting were subject.

Offers closed on 30 July 2004.

The Financial Markets Authority published the results of the Offer initiated by Sanofi-Synthélabo for the account of Aventis on 12 August 2004 in decision No 204C1006. The Offer was received positively.

4. Euronext Paris S.A. published, on 12 August 2004, an opinion on the result, settlement/delivery of the Offer and admission of the new Sanofi-Synthélabo shares under number 2004-2775, under the terms of which the settlement/ delivery of the Offer was set for 20 August 2004.

Consequently,

- confirms that the settlement/delivery of the Offer took place on 20 August 2004,

- records lifting of the suspensive condition to which the decisions of the above-mentioned General Meeting were subject, and

- records:

    (i) the change of the Company's trade name to "Sanofi-Aventis", with effect from 20 August 2004, the date of the settlement/delivery of the Offer;

(ii) as a consequence of the change of trade name, that the following wording

"Article 2 - Name:

The Company shall have the trade name "Sanofi-Aventis", replaced the current text of Article 2 of the Articles of Association, and that

(iii) Jean-Marc Bruel, Jürgen Dormann, Jean-René Fourtou, Serge Kampf, Igor Landau, Hubert Markl, Klaus Pohle and Hermann Scholl were appointed as directors, with effect from 20 August 2004, the date of the settlement/delivery of the Offer, for a period of four years expiring after the Meeting called to rule on the accounts for the 2007 financial year; and

- confers all powers on the bearer of an extract from or of a copy of the present minutes for the purposes of fulfilling all formalities in respect of filing, announcements, and the like, that may pertain.

Jean- François Dehecq

[signature]

Chairman and Managing Director